Glaukos Corporation, a cutting-edge medical technology and pharmaceutical enterprise specializing in ophthalmology, is dedicated to creating contemporary therapies for the treatment of glaucoma, retinal diseases, and corneal disorders. Presently, its array of innovative stents - iStent, iStent inject, and iStent inject W micro-bypass -- are proving to be effective in managing mild-to-moderate open-angle glaucoma by improving the outflow of the eye's aqueous humor during cataract surgery. Additionally, the company has two products under development - iStent Infinite, a device that can be implanted to reduce intraocular pressure, and iDose TR, an injectable implant designed to deliver therapeutic doses of medications. Glaukos Corporation uses a combination of direct sales networks and international distributors to market its products. The company was founded in 1998 and is headquartered in Aliso Viejo, California.